Area of research
Genetics · Oncology
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Cancer Immunotherapy and Biomarkers, and Inflammatory Biomarkers in Disease Prognosis.
Efficacy of Adding Veliparib to Temozolomide for Patients With <i>MGMT</i>-Methylated Glioblastoma
A hitchhiker’s guide to cerebrospinal fluid biomarkers for neuro-oncology
Upper Tract Urothelial Carcinoma Complicated by Skeletal Muscle Metastases.
BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with <i>NF2</i>-related schwannomatosis and progressive vestibular schwannoma
Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1
Management and Long-term Outcomes of Adults With Medulloblastoma: A Single-Center Experience.
Teaching NeuroImage: Intracranial Solitary Fibrous Tumor With Liver Metastasis.
EXTH-77. EXTENDED HALF-LIFE IL-2 SYNERGIZES WITH Α-PD-1 FOR TREATMENT OF PRECLINICAL MURINE GLIOBLASTOMA MODELS
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastoma
A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma.
Prolonged response of recurrent <i>IDH</i> -wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab
Prolonged response of recurrent <i>IDH</i>-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab.
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study.
Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.
The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma.
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma